December 11th, 2017
jobs
homes

Menu
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jasper Therapeutics, Inc. - Class A Common Stock (NQ:JSPR)

2.470 +0.140 (+6.01%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Jasper Therapeutics, Inc. - Class A Common Stock

< Previous 1 2 Next >
Deadline Approaching: Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
From Law Offices of Howard G. Smith
Via Business Wire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – JSPR
From The Rosen Law Firm PA
Via GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Encourages Jasper Therapeutics, Inc. (JSPR) Shareholders To Inquire About Securities Fraud Class Action
From Glancy Prongay & Murray LLP
Via Business Wire
Faruqi & Faruqi Reminds Jasper Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 18 , 2025 - JSPR
From Faruqi & Faruqi LLP
Via GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers – JSPR
From Pomerantz LLP
Via GlobeNewswire
Law Offices of Howard G. Smith Encourages Jasper Therapeutics, Inc. (JSPR) Investors To Inquire About Securities Fraud Class Action
From Law Offices of Howard G. Smith
Via Business Wire
Law Offices of Frank R. Cruz Encourages Jasper Therapeutics, Inc. (JSPR) Investors To Inquire About Securities Fraud Class Action
From The Law Offices of Frank R. Cruz
Via Business Wire
JASPER ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Jasper Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Securities Fraud Investigation Into Jasper Therapeutics, Inc. (JSPR) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
Jasper Therapeutics, Inc. (JSPR) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – JSPR
From DJS Law Group
Via Business Wire
Securities Fraud Investigation Into Jasper Therapeutics, Inc. (JSPR) Announced – Investors Who Lost Money Urged to Contact the Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
JSPR Stockholder Alert: Robbins LLP Reminds Investors of the Securities Fraud Class Action Against Jasper Therapeutics, Inc.
From Robbins LLP
Via GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper
From Faruqi & Faruqi, LLP
Via Business Wire
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – JSPR
From The Rosen Law Firm PA
Via GlobeNewswire
Rosen Law Firm Urges Jasper Therapeutics, Inc. (NASDAQ: JSPR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR
From Pomerantz LLP
Via GlobeNewswire
JSPR Investors Have Opportunity to Join Jasper Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR
From Pomerantz LLP
Via GlobeNewswire
Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Jasper Therapeutics, Inc.
Via GlobeNewswire
Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Jasper Therapeutics, Inc.
Via GlobeNewswire
Jasper Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
From Jasper Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.